SynthesisBipolar disorders2026
Towards a Safe and Effective Lithium Therapeutic Range for Older Adults With Bipolar Disorder: An ISBD Task Force Systematic Review.
Synthesis in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLithium is recommended as the first-line maintenance treatment for older adults with bipolar disorder (OABD). However, age-related reduction in renal clearance, heightened sensitivity to adverse effects, and drug interactions increase the risk of toxicity and necessitate lower therapeutic serum levels in this population. Despite expert consensus supporting age-adjusted targets, most clinical laboratories still do not report age-specific therapeutic ranges. We conducted a systematic review on recommended serum lithium levels in OABD to update evidence supporting age-specific therapeutic ranges for safe and effective lithium management.
methodsWe searched Medline, PsycINFO, Embase, and Cochrane Central Register of Controlled Trials since 2017 for studies analyzing lithium serum levels in individuals with bipolar disorder ≥ 60 years. Two reviewers independently screened titles, abstracts, and full texts. We used the National Institutes of Health Quality Assessment Tool to assess methodological quality.
resultsFourteen studies, including 8808 older adults using lithium, met inclusion criteria. All studies were observational with cross-sectional or cohort designs. Mean or median lithium levels ranged from 0.47-0.67 mmol/L. Levels of 0.82-1.00 mmol/L were associated with increased side effects or early toxicity signs, while levels of 1.20-1.25 mmol/L were overtly toxic. Impaired renal function and concomitant use of diuretics, ACE inhibitors, and NSAIDs required closer monitoring for toxicity.
conclusionsThese findings are consistent with age-adjusted lithium therapeutic targets in older adults and provide additional observational support for clinical laboratories to adopt age-specific therapeutic ranges. Clinicians should consider individualized monitoring accounting for age-related physiological changes and medication interactions to ensure safer and effective lithium therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.